LINE-1 hypomethylation is associated with poor outcomes in locoregionally advanced oropharyngeal cancer.


Journal

Clinical epigenetics
ISSN: 1868-7083
Titre abrégé: Clin Epigenetics
Pays: Germany
ID NLM: 101516977

Informations de publication

Date de publication:
12 Dec 2022
Historique:
received: 02 08 2022
accepted: 22 11 2022
entrez: 12 12 2022
pubmed: 13 12 2022
medline: 15 12 2022
Statut: epublish

Résumé

Currently, human papillomavirus (HPV) positivity represents a strong prognostic factor for both reduced risk of relapse and improved survival in patients with oropharyngeal squamous cell carcinoma (OPSCC). However, a subset of HPV-positive OPSCC patients still experience poor outcomes. Furthermore, HPV-negative OPSCC patients, who have an even higher risk of relapse, are still lacking suitable prognostic biomarkers for clinical outcome. Here, we evaluated the prognostic value of LINE-1 methylation level in OPSCC patients and further addressed the relationship between LINE-1 methylation status and p53 protein expression as well as genome-wide/gene-specific DNA methylation. In this study, DNA was extracted from 163 formalin-fixed paraffin-embedded tissue samples retrospectively collected from stage III-IVB OPSCC patients managed with curative intent with up-front treatment. Quantitative methylation-specific PCR revealed that LINE-1 hypomethylation was directly associated with poor prognosis (5-year overall survival-OS: 28.1% for LINE-1 methylation < 35% vs. 69.1% for ≥ 55%; p < 0.0001). When LINE-1 methylation was dichotomized as < 55% versus ≥ 55%, interaction with HPV16 emerged: compared with hypermethylated HPV16-positive patients, subjects with hypomethylated HPV16-negative OPSCC reported an adjusted higher risk of death (HR 4.83, 95% CI 2.24-10.38) and progression (HR 4.54, 95% CI 2.18-9.48). Tumor protein p53 (TP53) gene is often mutated and overexpressed in HPV-negative OPSCC. Since p53 has been reported to repress LINE-1 promoter, we then analyzed the association between p53 protein expression and LINE-1 methylation levels. Following p53 immunohistochemistry, results indicated that among HPV16-negative patients with p53 ≥ 50%, LINE-1 methylation levels declined and remained stable at approximately 43%; any HPV16-positive patient reported p53 ≥ 50%. Finally, DNA methylation analysis demonstrated that genome-wide average methylation level at cytosine-phosphate-guanine sites was significantly lower in HPV16-negative OPSCC patients who relapsed within two years. The subsequent integrative analysis of gene expression and DNA methylation identified 20 up-regulated/hypomethylated genes in relapsed patients, and most of them contained LINE-1 elements in their promoter sequences. Evaluation of the methylation level of LINE-1 may help in identifying the subset of OPSCC patients with bad prognosis regardless of their HPV status. Aberrant LINE-1 hypomethylation might occur along with TP53 mutations and lead to altered gene expression in OPSCC.

Sections du résumé

BACKGROUND AND PURPOSE OBJECTIVE
Currently, human papillomavirus (HPV) positivity represents a strong prognostic factor for both reduced risk of relapse and improved survival in patients with oropharyngeal squamous cell carcinoma (OPSCC). However, a subset of HPV-positive OPSCC patients still experience poor outcomes. Furthermore, HPV-negative OPSCC patients, who have an even higher risk of relapse, are still lacking suitable prognostic biomarkers for clinical outcome. Here, we evaluated the prognostic value of LINE-1 methylation level in OPSCC patients and further addressed the relationship between LINE-1 methylation status and p53 protein expression as well as genome-wide/gene-specific DNA methylation.
RESULTS RESULTS
In this study, DNA was extracted from 163 formalin-fixed paraffin-embedded tissue samples retrospectively collected from stage III-IVB OPSCC patients managed with curative intent with up-front treatment. Quantitative methylation-specific PCR revealed that LINE-1 hypomethylation was directly associated with poor prognosis (5-year overall survival-OS: 28.1% for LINE-1 methylation < 35% vs. 69.1% for ≥ 55%; p < 0.0001). When LINE-1 methylation was dichotomized as < 55% versus ≥ 55%, interaction with HPV16 emerged: compared with hypermethylated HPV16-positive patients, subjects with hypomethylated HPV16-negative OPSCC reported an adjusted higher risk of death (HR 4.83, 95% CI 2.24-10.38) and progression (HR 4.54, 95% CI 2.18-9.48). Tumor protein p53 (TP53) gene is often mutated and overexpressed in HPV-negative OPSCC. Since p53 has been reported to repress LINE-1 promoter, we then analyzed the association between p53 protein expression and LINE-1 methylation levels. Following p53 immunohistochemistry, results indicated that among HPV16-negative patients with p53 ≥ 50%, LINE-1 methylation levels declined and remained stable at approximately 43%; any HPV16-positive patient reported p53 ≥ 50%. Finally, DNA methylation analysis demonstrated that genome-wide average methylation level at cytosine-phosphate-guanine sites was significantly lower in HPV16-negative OPSCC patients who relapsed within two years. The subsequent integrative analysis of gene expression and DNA methylation identified 20 up-regulated/hypomethylated genes in relapsed patients, and most of them contained LINE-1 elements in their promoter sequences.
CONCLUSIONS CONCLUSIONS
Evaluation of the methylation level of LINE-1 may help in identifying the subset of OPSCC patients with bad prognosis regardless of their HPV status. Aberrant LINE-1 hypomethylation might occur along with TP53 mutations and lead to altered gene expression in OPSCC.

Identifiants

pubmed: 36503584
doi: 10.1186/s13148-022-01386-5
pii: 10.1186/s13148-022-01386-5
pmc: PMC9743592
doi:

Substances chimiques

Tumor Suppressor Protein p53 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

171

Subventions

Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG-23068
Organisme : Regione Campania
ID : POR Campania FESR 2014/2020 - Azione 1.5, grant GENOMAeSALUTE, CUP B41C17000080007 and RIS3 'La Campania lotta contro il cancro,' grant Rare-Plat-Net, CUP B63D18000380007
Organisme : Centro di Riferimento Oncologico
ID : 5x1000 Intramural Grant
Organisme : Centro di Riferimento Oncologico
ID : 5x1000 Intramural Grant
Organisme : Ministero della Salute
ID : Ricerca Corrente

Informations de copyright

© 2022. The Author(s).

Références

Clin Epigenetics. 2021 Jul 22;13(1):142
pubmed: 34294135
Clin Cancer Res. 2010 Apr 15;16(8):2418-26
pubmed: 20371677
Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):E89-98
pubmed: 23236145
PLoS One. 2011;6(8):e23332
pubmed: 21829728
Genes Cancer. 2016 Mar;7(3-4):136-47
pubmed: 27382437
J Oncol. 2021 Oct 15;2021:9931984
pubmed: 34691179
Cell. 1991 Nov 1;67(3):547-56
pubmed: 1657399
Oncotarget. 2020 Sep 29;11(39):3590-3600
pubmed: 33062195
Am J Pathol. 2014 May;184(5):1280-6
pubmed: 24607009
Nat Rev Cancer. 2017 Jul;17(7):415-424
pubmed: 28642606
Oral Oncol. 2018 Aug;83:127-133
pubmed: 30098768
BMC Cancer. 2019 Jan 14;19(1):64
pubmed: 30642292
Laryngoscope Investig Otolaryngol. 2017 Jan 17;2(1):10-18
pubmed: 28894817
Epigenomics. 2018 Mar;10(3):277-288
pubmed: 29264942
Mod Pathol. 2017 Mar;30(3):382-392
pubmed: 27934876
Clin Cancer Res. 2011 Jul 1;17(13):4225-31
pubmed: 21558408
Sci Rep. 2020 Jun 19;10(1):9970
pubmed: 32561788
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Cells. 2020 Sep 02;9(9):
pubmed: 32887319
Radiother Oncol. 2016 Feb;118(2):342-9
pubmed: 26952933
F1000Res. 2014 Jul 01;3:153
pubmed: 25254104
Viruses. 2021 Jul 09;13(7):
pubmed: 34372532
Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):E5526-E5535
pubmed: 29802231
Mod Pathol. 2011 Sep;24(9):1248-53
pubmed: 21552211
Head Neck. 2019 Nov;41(11):3833-3841
pubmed: 31414564
Sci Rep. 2020 Oct 1;10(1):16208
pubmed: 33004905
Mutat Res Rev Mutat Res. 2017 Apr - Jun;772:36-50
pubmed: 28528689
J Natl Cancer Inst. 2016 Jan 28;108(6):djv403
pubmed: 26823521
Lancet. 2019 Jan 5;393(10166):40-50
pubmed: 30449625
Int J Cancer. 2015 Apr 1;136(7):1494-503
pubmed: 24622970
Int J Mol Sci. 2022 Feb 25;23(5):
pubmed: 35269693
Pathol Oncol Res. 2019 Jul;25(3):1047-1058
pubmed: 30099696
Cancer Discov. 2013 Jul;3(7):761-9
pubmed: 23619167
Genome Med. 2017 Apr 5;9(1):33
pubmed: 28381277
Clin Chim Acta. 2019 Jun;493:52-62
pubmed: 30776360
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
N Engl J Med. 2007 Dec 20;357(25):2552-61
pubmed: 18094376
Acta Otolaryngol. 2021 Jul;141(7):724-728
pubmed: 34101529
Nat Commun. 2019 Sep 19;10(1):4278
pubmed: 31537801
Oncotarget. 2016 Oct 4;7(40):64910-64920
pubmed: 27626311
J Surg Oncol. 2021 Nov;124(6):962-966
pubmed: 34595766
Cancer. 2021 Sep 1;127(17):3092-3106
pubmed: 33957701
Clin Epigenetics. 2017 Jan 13;9:1
pubmed: 28149329
Thorac Cancer. 2022 Feb;13(3):369-379
pubmed: 34951127
Nat Genet. 2009 May;41(5):563-71
pubmed: 19377475
Med Sci Monit. 2018 May 09;24:3024-3033
pubmed: 29739919
Clin Epigenetics. 2017 Nov 28;9:124
pubmed: 29209433
Clin Epigenetics. 2017 May 30;9:58
pubmed: 28572862
Gut. 2014 Apr;63(4):635-46
pubmed: 23704319
Acta Oncol. 2008;47(4):600-7
pubmed: 18465328
Genes Dev. 2016 Jan 1;30(1):64-77
pubmed: 26701264
PLoS Genet. 2010 Apr 22;6(4):e1000917
pubmed: 20421991
Oral Oncol. 2020 Dec;111:104981
pubmed: 32873464
World J Surg Oncol. 2021 Jan 26;19(1):29
pubmed: 33499882
Nat Rev Genet. 2011 Feb;12(2):123-35
pubmed: 21221116
Oral Oncol. 2020 Jan;100:104488
pubmed: 31835137
Front Cell Dev Biol. 2020 Aug 07;8:657
pubmed: 32850797
FEBS J. 2022 Mar;289(5):1160-1179
pubmed: 33471418
Cancer Genet. 2020 Jun;244:21-29
pubmed: 32088612
J Cell Biochem. 2016 Dec;117(12):2682-2692
pubmed: 27166782
Genes Dev. 2020 Nov 1;34(21-22):1439-1451
pubmed: 33060137
Clin Epigenetics. 2019 May 14;11(1):77
pubmed: 31088544

Auteurs

Mariateresa Casarotto (M)

Unit of Immunopathology and Cancer Biomarkers, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.

Valentina Lupato (V)

Division of Otolaryngology, General Hospital "S. Maria Degli Angeli", Pordenone, Italy.

Giorgio Giurato (G)

Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Baronissi, SA, Italy.
Genome Research Center for Health, Campus of Medicine, University of Salerno, Baronissi, SA, Italy.

Roberto Guerrieri (R)

Unit of Immunopathology and Cancer Biomarkers, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.

Sandro Sulfaro (S)

Division of Pathology, General Hospital "S. Maria Degli Angeli", Pordenone, Italy.

Annamaria Salvati (A)

Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Baronissi, SA, Italy.
Genome Research Center for Health, Campus of Medicine, University of Salerno, Baronissi, SA, Italy.
Medical Genomics Program, AOU 'SS. Giovanni di Dio e Ruggi d'Aragona', University of Salerno, Salerno, Italy.

Elisa D'Angelo (E)

Department of Radiation Oncology, University Hospital of Modena, Modena, Italy.

Carlo Furlan (C)

Department of Radiation Oncology, General Hospital "San Martino", Belluno, Italy.

Anna Menegaldo (A)

Unit of Otolaryngology, AULSS 2 - Marca Trevigiana, Treviso, Italy.

Lorena Baboci (L)

Unit of Immunopathology and Cancer Biomarkers, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.

Barbara Montico (B)

Unit of Immunopathology and Cancer Biomarkers, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.

Irene Turturici (I)

Division of Radiotherapy, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, PN, Italy.

Riccardo Dolcetti (R)

Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, 3010, Australia.
Department of Microbiology and Immunology, The University of Melbourne, Melbourne, VIC, 3010, Australia.

Salvatore Romeo (S)

Department of Services of Diagnosis and Care, Santorso Hospital, Santorso, VI, Italy.

Vittorio Baggio (V)

Department of Radiation Oncology, Treviso Regional Hospital, Treviso, Italy.

Stefania Corrado (S)

Department of Anatomy and Pathology, University Hospital of Modena, Modena, Italy.

Gianluca Businello (G)

Department of Pathology, Treviso Regional Hospital, Treviso, Italy.

Maria Guido (M)

Department of Pathology, Treviso Regional Hospital, Treviso, Italy.
Department of Medicine (DIMED), University of Padova, Padova, Italy.

Alessandro Weisz (A)

Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Baronissi, SA, Italy.
Genome Research Center for Health, Campus of Medicine, University of Salerno, Baronissi, SA, Italy.
Medical Genomics Program, AOU 'SS. Giovanni di Dio e Ruggi d'Aragona', University of Salerno, Salerno, Italy.

Vittorio Giacomarra (V)

Division of Otolaryngology, General Hospital "S. Maria Degli Angeli", Pordenone, Italy.

Giovanni Franchin (G)

Division of Radiotherapy, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, PN, Italy.

Agostino Steffan (A)

Unit of Immunopathology and Cancer Biomarkers, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.

Luca Sigalotti (L)

Oncogenetics and Functional Oncogenomics Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.

Emanuela Vaccher (E)

Division of Medical Oncology A, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.

Paolo Boscolo-Rizzo (P)

Section of Otolaryngology, Department of Neurosciences, University of Padova, Treviso, Italy.

Polesel Jerry (P)

Unit of Cancer Epidemiology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.

Giuseppe Fanetti (G)

Division of Radiotherapy, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, PN, Italy.

Elisabetta Fratta (E)

Unit of Immunopathology and Cancer Biomarkers, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy. efratta@cro.it.
Division of Immunopathology and Cancer Biomarkers, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Via Franco Gallini, 2, 33081, Aviano, PN, Italy. efratta@cro.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH